We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

HospiMedica

Download Mobile App
Recent News AI Critical Care Surgical Techniques Patient Care Health IT Point of Care Business Focus

AstraZeneca Oxford COVID-19 Vaccine Resumes Clinical Trials in UK; Launch by 2020 End Still Achievable

By HospiMedica International staff writers
Posted on 14 Sep 2020
Print article
Illustration
Illustration
AstraZeneca (Cambridgeshire, England) has resumed clinical trials for its COVID-19 vaccine, following confirmation by the Medicines Health Regulatory Authority (MHRA) that it was safe to do so.

AstraZeneca is conducting trials of its adenovirus vector-based COVID-19 vaccine candidate, AZD1222, developed by the University of Oxford (Oxford, UK). However, a participant in the Phase 3 trial of the company’s experimental COVID-19 vaccine candidate had developed a serious spinal inflammatory disorder, forcing it to halt the study. The standard review process triggered a voluntary pause to vaccination across all global trials to allow review of safety data by independent committees, and international regulators.

The UK committee has now concluded its investigations and recommended to the MHRA that trials in the UK are safe to resume. All trial investigators and participants will be updated with the relevant information and this will be disclosed on global clinical registries, according to the clinical trial and regulatory standards. AstraZeneca has reaffirmed its commitment to the safety of trial participants and the highest standards of conduct in clinical trials. The company has said that it will continue to work with health authorities across the world and be guided as to when other clinical trials can resume.

Despite the interruption in the clinical trials, the company’s chief executive, Pascal Soriot, has expressed confidence that a year-end launch of its COVID-19 vaccine was still possible, according to a report by the Guardian. Speaking at an event, Soriot said “I still think we are on track for having a set of data that we would submit before the end of the year” for regulatory approval. They “could still have a vaccine by the end of this year, early next year”, depending on how fast the regulator moves, he added.

Related Links:
AstraZeneca
University of Oxford


Gold Member
Disposable Protective Suit For Medical Use
Disposable Protective Suit For Medical Use
Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
Silver Member
Compact 14-Day Uninterrupted Holter ECG
NR-314P
New
Examination Data Management Software
DiVAS 2.8

Print article

Channels

Critical Care

view channel
Image: The stretchable microneedle electrode arrays (Photo courtesy of Zhao Research Group)

Stretchable Microneedles to Help In Accurate Tracking of Abnormalities and Identifying Rapid Treatment

The field of personalized medicine is transforming rapidly, with advancements like wearable devices and home testing kits making it increasingly easy to monitor a wide range of health metrics, from heart... Read more

Patient Care

view channel
Image: The portable, handheld BeamClean technology inactivates pathogens on commonly touched surfaces in seconds (Photo courtesy of Freestyle Partners)

First-Of-Its-Kind Portable Germicidal Light Technology Disinfects High-Touch Clinical Surfaces in Seconds

Reducing healthcare-acquired infections (HAIs) remains a pressing issue within global healthcare systems. In the United States alone, 1.7 million patients contract HAIs annually, leading to approximately... Read more

Health IT

view channel
Image: First ever institution-specific model provides significant performance advantage over current population-derived models (Photo courtesy of Mount Sinai)

Machine Learning Model Improves Mortality Risk Prediction for Cardiac Surgery Patients

Machine learning algorithms have been deployed to create predictive models in various medical fields, with some demonstrating improved outcomes compared to their standard-of-care counterparts.... Read more

Point of Care

view channel
Image: The Quantra Hemostasis System has received US FDA special 510(k) clearance for use with its Quantra QStat Cartridge (Photo courtesy of HemoSonics)

Critical Bleeding Management System to Help Hospitals Further Standardize Viscoelastic Testing

Surgical procedures are often accompanied by significant blood loss and the subsequent high likelihood of the need for allogeneic blood transfusions. These transfusions, while critical, are linked to various... Read more